Navigation Links
Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation

Novel Approach to Address Growing Problem of Antibiotic Resistance Published in Nature Biotechnology

VANCOUVER, British Columbia, March 26, 2007 /PRNewswire/ -- Inimex Pharmaceuticals Inc.'s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.

The paper, which highlights the work of Inimex and its co-founders Dr. Bob Hancock and Dr. Brett Finlay, shows that IDR-1 protected mice against Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) infections. With as little as one dose, IDR-1 increased the levels of key immune system fighter cells, which caused prolonged enhancement of the host immune system's response to these antibiotic-resistant pathogens. A key finding was that the product eradicated the infections without increasing the levels of pro-inflammatory cytokines that are typically present during the first stage of immunity.

"The body's immune system naturally possesses the tools to fight infections," said John North, president and chief executive officer of Inimex. "We're developing therapeutics that utilize this powerful innate response without the threat of a cytokine storm that can lead to sepsis."

Bob Hancock added: "The success of our product in controlling bacterial infection represents a novel approach at a time when antibiotic resistance is getting worse every day. With the decline of new antibiotic discovery, we desperately need new avenues of research for the treatment of super bugs."

Methicillin Resistant Staphylococcus (MRSA) and Vancomycin Resistant Enterococcus (VRE) cause infections that antibiotics can no longer treat and account for more than 90,000 deaths each year in North America alone. Inimex's goal is to develop IDR products as a new line of defense against pathogens that seek out residents of hospital and treatment centers whose immune systems are battered by age, disease or myelosuppressive medications.

The paper was published as Scott, M.G. et al. (2007) "An anti-infective peptide that selectively modulates the innate immune response" in Nature Biotechnology (April 2007, vol. 25 No. 4) and will be accessible online on March 25.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first-in-class drugs that selectively trigger the body's innate defenses without causing inflammation. IDRs have major market potential for infectious diseases, cancer and inflammatory disease. Inimex's investors include BDC Venture Capital, Canadian Medical Discovery Fund, Growthworks Capital, Discovery Capital and BC Advantage Fund. For more information, visit http://www.inimexpharma.com.

    Noonan Russo

    Andrew Villani or David Schull

    212-845-4262

    

    

andrew.villani@eurorscg.com david.schull@eurorscg.com

CONTACT: Andrew Villani, , or David Schull,, both of Noonan Russo, +1-212-845-4262, forInimex Pharmaceuticals Inc. andrew.villani@eurorscg.com david.schull@eurorscg.com

Web site: http://www.inimexpharma.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
5. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. PromegaExpress Expands Easy Access to Products with New Cabinet
8. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
9. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
Breaking Medicine Technology:
(Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... will be offered by the American Association of Integrative Medicine and available for ... healthcare providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With expansion ... Marshallville, Georgia, in early March. , The seed processing plant opened in Marshallville in ... since 2016. The new office allows opportunity for transition of Patten Seed operations to ...
Breaking Medicine News(10 mins):